OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
The tumour-necrosis-factor-family molecule osteoprotegerin ligand (OPGL; also known as TRANCE, RANKL and ODF) has been identified as a potential osteoclast differentiation factor and regulator of interactions between T cells and dendritic cells in vitro. Mice with a disrupted opgl gene show severe osteopetrosis and a defect in tooth eruption, and completely lack osteoclasts as a result of an inability of osteoblasts to support osteoclastogenesis. Although dendritic cells appear normal, opgl-deficient mice exhibit defects in early differentiation of T and B lymphocytes. Surprisingly, opgl-deficient mice lack all lymph nodes but have normal splenic structure and Peyer's patches. Thus OPGL is a new regulator of lymph-node organogenesis and lymphocyte development and is an essential osteoclast differentiation factor in vivo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Bone resorption is dependent on a cytokine known as RANKL (receptor activator of nuclear factor B ligand), a TNF family member that is essential for osteoclast formation, activity, and survival in normal and pathological states of bone remodeling.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [64]
In the citing paper
“In the absence of RANK or RANKL, osteoclasts cannot form, function, or survive (62-64, 110, 111).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [64]
In the citing paper
“RANK and RANKL knockout mice were virtual phenocopies of each other (62)(63)(64), which indicated that RANK and RANKL had few if any roles beyond their mutual interactions.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [64]
In the citing paper
“Another unexpected phenotype found in RANK and RANKL knockout mice was the total lack of lymph nodes (62,64).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [64]
In the citing paper
“Examination of mice genetically deficient in RANKL, RANK, or OPG also revealed no overt dendritic cell defects (62,64,170).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [64]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Self-citationOsteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Self-citationYasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,228
Inaba, K., Inaba, M., Romani, N., Aya, H., Deguchi, M., Ikehara, S., Muramatsu, S., & Steinman, R. M. (1992) · The Journal of experimental medicine · doi:10.1084/jem.176.6.1693 · Cited by 3,738
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.
Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuBose, R. F., Cosman, D., & Galibert, L. (1997) · Nature · doi:10.1038/36593 · Cited by 2,290
Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice
Soriano, P., Montgomery, C., Geske, R., & Bradley, A. (1991) · Cell · doi:10.1016/0092-8674(91)90499-o · Cited by 2,016
Yoshida, H., Hayashi, S.-I., Kunisada, T., Ogawa, M., Nishikawa, S., Okamura, H., Sudo, T., Shultz, L. D., & Nishikawa, S.-I. (1990) · Nature · doi:10.1038/345442a0 · Cited by 1,789
Self-citationManolagas, S. C., & Jilka, R. L. (1995) · New England Journal of Medicine · doi:10.1056/nejm199502023320506 · Cited by 1,668
Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice.
Peschon, J. J., Morrissey, P. J., Grabstein, K. H., Ramsdell, F. J., Maraskovsky, E., Gliniak, B. C., Park, L. S., Ziegler, S. F., Williams, D. E., Ware, C. B., et al. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.5.1955 · Cited by 1,555
c-Fos: a Key Regulator of Osteoclast-Macrophage Lineage Determination and Bone Remodeling
Grigoriadis, A. E., Wang, Z.-Q., Cecchini, M. G., Hofstetter, W., Felix, R., Fleisch, H. A., & Wagner, E. F. (1994) · Science · doi:10.1126/science.7939685 · Cited by 1,260
Cited by
Items 701–800 of 1,030
Aoki, K., DiDomenico, E., Sims, N. A., Mukhopadhyay, K., Neff, L., Houghton, A., Amling, M., Levy, J. B., Horne, W. C., & Baron, R. (1999) · Bone · doi:10.1016/s8756-3282(99)00174-x · Cited by 109
Ma, Q., Liang, M., Wu, Y., Ding, N., Duan, L., Yu, T., Bai, Y., Kang, F., Dong, S., Xu, J., et al. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.007625 · Cited by 107
de Molon, R. S., Vernal, R., Oliveira, G. E., Steffens, J. P., Ervolino, E., Theodoro, L. H., van den Beucken, J. J. J. P., & Tetradis, S. (2026) · Bone Research · doi:10.1038/s41413-025-00478-1 · Cited by 117
“121 Previous studies demonstrate that RANKL-de fi cient ( RANKL − / − ) 129 and RANK-de fi cient ( RANK − / − ) 130 mice develop severe osteopetrosis due to impaired osteoclast formation, highlighting the essential role of the RANKL – RANK pathway in bone resorption.”
Miyamoto, T., Arai, F., Ohneda, O., Takagi, K., Anderson, D. M., & Suda, T. (2000) · Blood · doi:10.1182/blood.v96.13.4335 · Cited by 110
Sánchez, C. J., Ward, C. L., Romano, D. R., Hurtgen, B. J., Hardy, S. K., Woodbury, R. L., Trevino, A. V., Rathbone, C. R., & Wenke, J. C. (2013) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-14-187 · Cited by 118
“Osteoblasts facilitate bone formation directly, through the deposition and calcification of bone matrix promoting new bone growth, and promote bone resorption indirectly by regulating the activity of osteoclasts by the production of two cytokines, the receptor activator of NF-kB ligand (RANK-L) and osteoprotegrin (OPG…”
BackgroundValverde, P., Kawai, T., & Taubman, M. A. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0301213 · Cited by 110
Ahn, K. S., Sethi, G., Chaturvedi, M. M., & Aggarwal, B. B. (2008) · International Journal of Cancer · doi:10.1002/ijc.23745 · Cited by 109
“RANKL can activate mature osteoclasts in vitro and can lead rapidly to the resorption of bone in vivo by activating preexisting osteoclasts.(11,12)”
BackgroundLineage-committed osteoclast precursors circulate in blood and settle down into bone
Muto, A., Mizoguchi, T., Udagawa, N., Ito, S., Kawahara, I., Abiko, Y., Arai, A., Harada, S., Kobayashi, Y., Nakamichi, Y., et al. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.490 · Cited by 120
“RANKL / mice (C57BL/6) were generated in one of the authors’ laboratories.((27)) All experiments were conducted in accordance with the guidelines for studies with laboratory animals of the Matsumoto Dental University Experimental Animal Committee.”
MethodSelf-citationOsteocyte regulation of orthodontic force-mediated tooth movement via RANKL expression
Ayumi, S., Ono, T., Hayashi, M., Takayanagi, H., Moriyama, K., & Nakashima, T. (2017) · Scientific Reports · doi:10.1038/s41598-017-09326-7 · Cited by 117
NF‐kB signaling blockade abolishes implant particle‐induced osteoclastogenesis
Clohisy, J. C., Hirayama, T., Frazier, E., Han, S., & Abu‐Amer, Y. (2004) · Journal of Orthopaedic Research · doi:10.1016/s0736-0266(03)00156-6 · Cited by 109
Zhu, J., Jia, X., Xiao, G., Kang, Y., Partridge, N. C., & Qin, L. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m705064200 · Cited by 109
Requirement for the NF-κB Family Member RelA in the Development of Secondary Lymphoid Organs
Alcamo, E., Hacohen, N., Schulte, L. C., Rennert, P. D., Hynes, R. O., & Baltimore, D. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011885 · Cited by 104
“However, this is unlikely, as TNFR1/RelA-deficient animals have normal numbers of embryonic CD4 CD3 IL-7R cells whereas these numbers are severely reduced in RANKL/TRANCE/OPGLdeficient animals (5); in addition, RANK- and RANKL/ TRANCE/OPGL-deficient mice lack teeth (3, 4), which TNFR1/RelA-deficient mice possess.”
BackgroundRANK-Fc: A therapeutic antagonist for RANK-L in myeloma
Sordillo, E. M., & Pearse, R. N. (2003) · Cancer · doi:10.1002/cncr.11134 · Cited by 114
Algate, K., Haynes, D. R., Bartold, P. M., Crotti, T. N., & Cantley, M. D. (2015) · Journal of Periodontal Research · doi:10.1111/jre.12339 · Cited by 122
Regulation of Osteoclast Differentiation and Function by Interleukin‐1
Nakamura, I., & Jimi, E. (2006) · Vitamins and hormones · doi:10.1016/s0083-6729(06)74015-8 · Cited by 115
Silvestrini, G., Ballanti, P., Patacchioli, F. R., Leopizzi, M., Gualtieri, N., Monnazzi, P., Tremante, E., Sardella, D., & BONUCCI, E. (2005) · The Histochemical Journal · doi:10.1007/s10735-004-3839-1 · Cited by 119
“…tissues (Simonet et al. 1997a, Lacey et al. 1998, Kartsogiannis et al. 1999), their relevance to bone metabolism is supported by the fact that transgenic mice overexpressing the OPG gene (Simonet et al. 1997a) and RANKL knockout mice (Kong et al. 1999) showed a remarkable osteopetrotic phenotype.”
BackgroundDioxins interfere with differentiation of osteoblasts and osteoclasts
Korkalainen, M., Kallio, E., Olkku, A., Nelo, K., Ilvesaro, J. M., Tuukkanen, J., Mahonen, A., & Viluksela, M. (2009) · Bone · doi:10.1016/j.bone.2009.02.019 · Cited by 114
TNF ligands and receptors in autoimmunity: an update
Mackay, F., & Kalled, S. L. (2002) · Current Opinion in Immunology · doi:10.1016/s0952-7915(02)00407-7 · Cited by 117
Marginal reticular cells: a stromal subset directly descended from the lymphoid tissue organizer
Katakai, T. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00200 · Cited by 98
Maruyama, K., Takada, Y., Ray, N., Kishimoto, Y., Penninger, J. M., Yasuda, H., & Matsuo, K. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.6.3799 · Cited by 105
“Mice lacking RANKL (7), RANK (8, 9), TRAF6 (10, 11), NF- B (p50 and p52) (12), c-Fos (13–15), or NFATc1 (16) develop osteopetrosis due to a differential block in the osteoclast lineage.”
BackgroundSelf-citationBekker, P. J., Holloway, D. L., Rasmussen, A. S., Murphy, R., Martin, S. W., Leese, P. T., Holmes, G. B., Dunstan, C. R., & DePaoli, A. M. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2005.20.12.2274 · Cited by 98
Self-citationOPG Production Matters Where It Happened
Tsukasaki, M., Asano, T., Muro, R., Huynh, N. C., Komatsu, N., Okamoto, K., Nakano, K., Okamura, T., Nitta, T., & Takayanagi, H. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108124 · Cited by 111
RANK links thymic regulatory T cells to fetal loss and gestational diabetes in pregnancy
Paolino, M., Koglgruber, R., Cronin, S. J. F., Uribesalgo, I., Rauscher, E., Harreiter, J., Schuster, M. K., Bancher‐Todesca, D., Pranjic, B., Novatchkova, M., et al. (2020) · Nature · doi:10.1038/s41586-020-03071-0 · Cited by 112
Self-citationMechanisms of osteoporosis after hematopoietic cell transplantation
Weilbaecher, K. N. (2000) · Transplantation and Cellular Therapy · doi:10.1016/s1083-8791(00)70039-5 · Cited by 113
How B cells influence bone biology in health and disease
Horowitz, M. C., Fretz, J. A., & Lorenzo, J. A. (2010) · Bone · doi:10.1016/j.bone.2010.06.011 · Cited by 105
“differentiation chimeric mice were made by injecting fetal liver cells from RANKL−/− or WT mice into sub-lethally irradiated Rag−/− mice [59].”
BackgroundMethodInfluentialOsteoclast activity modulates B-cell development in the bone marrow
Mansour, A., Anginot, A., Mancini, S. J. C., Schiff, C., Carle, G. F., Wakkach, A., & Blin‐Wakkach, C. (2011) · Cell Research · doi:10.1038/cr.2011.21 · Cited by 115
The KRN mouse model of inflammatory arthritis
Kyburz, D., & Corr, M. (2003) · Springer Seminars in Immunopathology · doi:10.1007/s00281-003-0131-5 · Cited by 118
“Hence, osteoclasts are absent in TRANCE/RANKL- deficient mice, which display severe osteopetrosis [20].”
BackgroundNAGASAWA, T., KOBAYASHI, H., KIJI, M., ARAMAKI, M., MAHANONDA, R., KOJIMA, T., MURAKAMI, Y., SAITO, M., MOROTOME, Y., & ISHIKAWA, I. (2002) · Clinical and Experimental Immunology · doi:10.1046/j.1365-2249.2002.01990.x · Cited by 106
Regulation of bone by the adaptive immune system in arthritis
Okamoto, K., & Takayanagi, H. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3323 · Cited by 119
Tumor Microenvironment Promotes Cancer Progression, Metastasis, and Therapeutic Resistance
Sung, S., Hsieh, C., Wu, D., Chung, L. W. K., & Johnstone, P. A. S. (2007) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2006.12.002 · Cited by 121
Cellular and molecular pathways of structural damage in rheumatoid arthritis
Steffen, U., & Schett, G. A. (2017) · Seminars in Immunopathology · doi:10.1007/s00281-017-0634-0 · Cited by 116
Efficacy of an orally active small-molecule inhibitor of RANKL in bone metastasis
Nakai, Y., Okamoto, K., Terashima, A., Ehata, S., Nishida, J., Imamura, T., Ono, T., & Takayanagi, H. (2019) · Bone Research · doi:10.1038/s41413-018-0036-5 · Cited by 110
Karsdal, M. A., Schett, G. A., Emery, P., Harari, O., Byrjalsen, I., Kenwright, A., Bay‐Jensen, A., & Platt, A. (2012) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2012.01.004 · Cited by 110
Evolving concepts in the pathogenesis of hairy-cell leukaemia
Tiacci, E., Liso, A., Piris, M. A., & Falini, B. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1888 · Cited by 115
“, for lymph node development (such as TNFSF11 , also known as RANK-ligand”
BackgroundYi, T., Lee, H., Cha, J., Ko, S., Kim, H., Shin, H., Woo, K. M., Ryoo, H., Kim, G., & Baek, J. (2008) · Journal of Cellular Physiology · doi:10.1002/jcp.21511 · Cited by 112
“…formed from macrophage/monocyte lineage cells in a differentiation process that is critically regulated by key cytokine molecules such as macrophage-colony stimulating factor (M-CSF) and receptor activator of nuclear factor kB ligand (RANKL) (Lacey et al., 1998; Kong et al., 1999; Li et al., 2000).”
BackgroundOnoe, Y., Miyaura, C., Ito, M., Ohta, H., Nozawa, S., & Suda, T. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.3.541 · Cited by 106
Atkins, G. J., Bouralexis, S., Haynes, D. R., Graves, S. E., Geary, S. M., Evdokiou, A., Zannettino, A. C. W., Hay, S., & Findlay, D. M. (2001) · Bone · doi:10.1016/s8756-3282(01)00404-5 · Cited by 105
Zhou, L., Liu, Q., Yang, M., Wang, T., Yao, J., Cheng, J., Yuan, J., Lin, X., Zhao, J., Tickner, J. C., et al. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2771 · Cited by 105
“activation-induced cytokine (TRANCE), and osteoclast differentiation factor (ODF), is a critical cytokine for the formation and activation of osteoclasts [5-7].”
BackgroundRANKL-responsive epigenetic mechanism reprograms macrophages into bone-resorbing osteoclasts
Bae, S., Kim, K., Kang, K., Kim, H., Lee, M. J., Oh, B., Kaneko, K., Ma, S., Choi, J., Kwak, H., et al. (2022) · Cellular and Molecular Immunology · doi:10.1038/s41423-022-00959-x · Cited by 108
Pamidronate is an effective treatment for osteoporosis in patients with beta‐thalassaemia
Voskaridou, E., Terpos, E., Spina, G., Palermos, J., Rahemtulla, A., Loutradi, A., & Loukopoulos, D. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04657.x · Cited by 105
Xing, L., Venegas, A. M., Chen, A. Y.-C., Garrett-Beal, L. J., Boyce, B. F., VARMUS, H. E., & Schwartzberg, P. L. (2001) · Genes & Development · doi:10.1101/gad.840301 · Cited by 111
“In bone, this may be particularly useful for the treatment both of osteoporosis and of rheumatoid arthritis, where blocking RANKL activity has been found to decrease bone destruction in animal models (Kong et al. 1999a).”
BackgroundBharti, A. C., Takada, Y., Shishodia, S., & Aggarwal, B. B. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m308062200 · Cited by 112
Crystal Structure of Human RANKL Complexed with Its Decoy Receptor Osteoprotegerin
Luan, X., Lu, Q., Jiang, Y., Zhang, S., Wang, Q., Yuan, H., Zhao, W., Wang, J., & Wang, X. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103387 · Cited by 112
Khastgir, G., Studd, J., Holland, N., Alaghband-Zadeh, J., Fox, S., & Chow, J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.1.7161 · Cited by 97
Transcriptional Mechanisms of Bone Morphogenetic Protein-induced Osteoprotegrin Gene Expression
Wan, M., Shi, X., Feng, X., & Cao, X. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m006918200 · Cited by 119
Ibáñez, L., Rouleau, M., Wakkach, A., & Blin-Wakkach, C. (2019) · Joint Bone Spine · doi:10.1016/j.jbspin.2018.02.008 · Cited by 103
Danks, L., & Takayanagi, H. (2013) · The Journal of Biochemistry · doi:10.1093/jb/mvt049 · Cited by 119
Matrix metalloproteinases as master regulators of the vicious cycle of bone metastasis
Lynch, C. C. (2010) · Bone · doi:10.1016/j.bone.2010.06.007 · Cited by 108
Fujiwara, Y., Piemontese, M., Liu, Y., Thostenson, J. D., Xiong, J., & O'Brien, C. A. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.742452 · Cited by 99
“The cytokine receptor activator of NF B ligand (RANKL),(2) encoded by the Tnfsf11 gene, is essential for osteoclast formation but plays important roles in other processes such as mammary gland and lymphocyte development (2, 3).”
BackgroundRANKL Inhibitors Induce Osteonecrosis of the Jaw in Mice With Periapical Disease
Aghaloo, T. L., Cheong, S., Bezouglaia, O., Kostenuik, P. J., Atti, E., Dry, S., Pirih, F. Q. M., & Tetradis, S. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2097 · Cited by 109
“RANKL knockoutmice demonstrate decreased osteoclast numbers, defective bone remodeling, severe osteopetrosis, and no tooth eruption.((56,57)) RANKL binding to RANK induces osteoclast differentiation and function.”
BackgroundDexamethasone promotes osteoclastogenesis by inhibiting osteoprotegerin through multiple levels
Kondo, T., Kitazawa, R., Yamaguchi, A., & Kitazawa, S. (2008) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21414 · Cited by 103
“E-mail: kitazawa@med.kobe-u.ac.jp Received 22 January 2007; Accepted 18 April 2007 DOI 10.1002/jcb.21414 et al., 1997b; Lacey et al., 1998;Nakagawaet al., 1998; Quinn et al., 1998; Yasuda et al., 1998].”
InfluentialCentral control of bone formation
Takeda, S., & Karsenty, G. (2001) · Journal of Bone and Mineral Metabolism · doi:10.1007/s007740170042 · Cited by 115
“Moreover, even molecules thought of as cytokines, such as osteoprotegerin (OPG) and receptor activator of NF-kB (RANK) ligand, are able to regulate osteoclast differentiation systemically [8–13].”
BackgroundCannabinoids and the skeleton: From marijuana to reversal of bone loss
Bab, I., Zimmer, A. D., & Melamed, E. (2009) · Annals of Medicine · doi:10.1080/07853890903121025 · Cited by 108
Jiang, Y., Mishima, H., Sakai, S., Liu, Y., Ohyabu, Y., & Uemura, T. (2008) · Journal of Orthopaedic Research® · doi:10.1002/jor.20623 · Cited by 108
“Deletion of the RANKL gene in mice resulted in severe osteopetrosis and a complete lack of osteoclasts as a result of an inability of osteoblasts to support osteoclastogenesis.(48) Although osteoprotegerin (OPG), a decoy receptor for RANKL, is also involved in osteoclastogenesis by inhibiting osteoclast differentiatio…”
BackgroundThe new concept of periodontal disease pathogenesis requires new and novel therapeutic strategies
Taubman, M. A., Kawai, T., & Han, X. (2007) · Journal Of Clinical Periodontology · doi:10.1111/j.1600-051x.2007.01065.x · Cited by 117
Cytokines regulating osteoclast formation and function
Lee, S.-K., & Lorenzo, J. (2006) · Current Opinion in Rheumatology · doi:10.1097/01.bor.0000231911.42666.78 · Cited by 104
Efficacy of ex vivo OPG gene therapy in preventing wear debris induced osteolysis
Goater, J. J., O'Keefe, R. J., Rosier, R. N., Puzas, J. E., & Schwarz, E. M. (2002) · Journal of Orthopaedic Research · doi:10.1016/s0736-0266(01)00083-3 · Cited by 103
Experimental infection of warthos (Phacochoerus aethiopicus) with African swine fever virus.
Thomson, G. R., Gainaru, M. D., & van Dellen, A. F. (1980) · PubMed · Cited by 134
M-CSF neutralization and Egr-1 deficiency prevent ovariectomy-induced bone loss
Cenci, S., Weitzmann, M. N., Gentile, M. A., Aisa, M. C., & Pacifici, R. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8672 · Cited by 103
“The formation of mature OCs is completely dependent on the presence of both OPGL and M-CSF, as demonstrated by the absence of OC development in mice lacking the expression of either factor (4, 9, 10).”
BackgroundSo, T., Lee, S., & Croft, M. (2006) · International Journal of Hematology · doi:10.1532/ijh97.05120 · Cited by 109
Ofotokun, I., McIntosh, E. B., & Weitzmann, M. N. (2011) · Current HIV/AIDS Reports · doi:10.1007/s11904-011-0099-z · Cited by 107
“The clinical implications of the immuno-skeletal interface are underscored by the changes in bone turnover and loss of bone mineral density (BMD) commonly associated with conditions such as rheumatoid arthritis [2], periodontal infection [3], inflammatory bowel disease [4], type I and II diabetes [5–7], systemic lupus…”
BackgroundActivating transcription factor 4 regulates osteoclast differentiation in mice
Cao, H., Yu, S., Yao, Z., Galson, D. L., Jiang, Y., Zhang, X., Fan, J., Lu, B., Guan, Y., Luo, M., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42106 · Cited by 98
Roles for NF-κB and c-Fos in osteoclasts
Boyce, B. F., Yamashita, T., Yao, Z., Zhang, Q., Li, F., & Xing, L. (2005) · Journal of Bone and Mineral Metabolism · doi:10.1007/bf03026317 · Cited by 109
“the essential role of the receptor activator of NF-kappaB ligand (RANKL) and its cognate receptor, RANK, in osteoclast formation and their relationship with OPG and NF-~:B were discovered, also serendipitously [10-13].”
Metastatic prostate cancer and the bone: significance and therapeutic options
Gartrell, B. A., Coleman, R., Efstathiou, E., Fizazi, K., Logothetis, C. J., Smith, M. R., Sonpavde, G., Sartor, O., & Saad, F. (2015) · European Urology · doi:10.1016/j.eururo.2015.06.039 · Cited by 101
“RANKL-RANK signaling is the key driver of osteoclast formation and function with mouse models deficient in either gene displaying impaired osteoclastogenesis and a condition termed osteopetrosis characterized by dense and brittle bones [18,19].”
BackgroundInflammatory Cell Migration in Rheumatoid Arthritis: A Comprehensive Review
Nevius, E., Gomes, A. C., & Pereira, J. P. (2015) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-015-8520-9 · Cited by 112
Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice
Molyneux, S. D., Di Grappa, M. A., Beristain, A. G., McKee, T. D., Wai, D. H., Paderova, J., Kashyap, M., Hu, P., Maiuri, T., Narala, S. R., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42391 · Cited by 99
“Indeed, RANKL is an essential regulator of osteoclast differentiation, and Tnfsf11–/– mice are severely osteopetrotic, due to a lack of osteoclasts (57).”
Self-citationDenosumab in patients with cancer—a surgical strike against the osteoclast
Brown, J. E., & Coleman, R. E. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.197 · Cited by 105
“Mice deficient in either RANKL or RANK lack osteoclasts and exhibit severe osteopetrosis”
BackgroundGuerrini, M. M., Okamoto, K., Komatsu, N., Sawa, S., Danks, L., Penninger, J. M., Nakashima, T., & Takayanagi, H. (2015) · Immunity · doi:10.1016/j.immuni.2015.10.017 · Cited by 103
“Tnfsf11flox/D Lck-cre mice grew normally without any bone defects (Nakashima et al., 2011) and the numbers of conventional and plasmacytoid DCs were unaffected (Figures S1C and S1D), as in the case of Tnfsf11 / mice (Kong et al., 1999).”
BackgroundSelf-citationThe hypertrophic chondrocyte: To be or not to be.
Hallett, S. A., Ono, W., & Ono, N. (2021) · Histology and histopathology · doi:10.14670/hh-18-355 · Cited by 121
“RANKL is expressed by cells of the osteoblast lineage and facilitates osteoclast formation (Kong et al., 1999; Sobacchi et al., 2007).”
BackgroundBarreto, F. C., Barreto, D. V., Moysés, R. M. A., Neves, C. L., Jorgetti, V., Draibe, S. A., Canziani, M. E. F., & Carvalho, A. B. (2006) · Kidney International · doi:10.1038/sj.ki.5000311 · Cited by 105
Differential RET Signaling Pathways Drive Development of the Enteric Lymphoid and Nervous Systems
Patel, A., Harker, N., Moreira-Santos, L., Ferreira, M., Alden, K., Timmis, J., Foster, K., Garefalaki, A., Pachnis, P., Andrews, P., et al. (2012) · Science Signaling · doi:10.1126/scisignal.2002734 · Cited by 94
Anastasilakis, A. D., Toulis, K. A., Goulis, D. G., Pοlyzos, S. A., Delaroudis, S., Giomisi, A., & Terpos, E. (2009) · Hormone and Metabolic Research · doi:10.1055/s-0029-1224109 · Cited by 109
Marriott, I. (2004) · Immunologic Research · doi:10.1385/ir:30:3:291 · Cited by 104
Regulation of osteoclast activity
Greenfield, E. M., Bi, Y., & Miyauchi, A. (1999) · Life Sciences · doi:10.1016/s0024-3205(99)00156-3 · Cited by 119
Bolon, B., Carter, C., Daris, M., Morony, S., Capparelli, C., Hsieh, A., Mao, M., Kostenuik, P., Dunstan, C. R., Lacey, D. L., et al. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0245 · Cited by 100
Self-citationAn overview of bone cells and their regulating factors of differentiation.
Mohamed, A. M. (2008) · Europe PMC (PubMed Central) · Cited by 188
Pitari, M. R., Rossi, M., Amodio, N., Botta, C., Morelli, E., Federico, C., Gullà, A., Caracciolo, D., Di Martino, M. T., Arbitrio, M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4398 · Cited by 98
“The biological relevance of this system is demonstrated by the development of severe osteoporosis and osteopetrosis in OPG- and RANKL- knockout mice, respectively [6, 7].”
BackgroundKawaida, R., Ohtsuka, T., Okutsu, J., Takahashi, T., Kadono, Y., Oda, H., Hikita, A., Nakamura, K., Tanaka, S., & Furukawa, H. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021321 · Cited by 108
Nuclear Factor-kappaB in Autoimmunity: Man and Mouse
Miraghazadeh, B., & Cook, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00613 · Cited by 105
“Similarly, autoimmune phenotypes have been induced by deletion of CD40L, RANKL, or LTβR, the ligands crucial for inducing non-canonical signaling for mTEC maturation and maintenance (166, 185, 186).”
BackgroundTakuma, A., Kaneda, T., Sato, T., Ninomiya, S., Kumegawa, M., & Hakeda, Y. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300213200 · Cited by 100
The skeleton as an intracrine organ for vitamin D metabolism
Anderson, P., & Atkins, G. J. (2008) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2008.05.003 · Cited by 100
Lamothe, B., Lai, Y., Xie, M., Schneider, M. D., & Darnay, B. G. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.01225-12 · Cited by 99
“teopetrosis due to a complete failure to form osteoclasts (1, 2).”
BackgroundEstrogen, androgen, and the pathogenesis of bone fragility in women and men
Seeman, E. (2004) · Current Osteoporosis Reports · doi:10.1007/s11914-004-0016-0 · Cited by 111
Ju, J. H., Cho, M.-L., Moon, Y.-M., Oh, H.-J., Park, J.-S., Jhun, J.-Y., Min, S.-Y., Cho, Y.-G., Park, K.-S., Yoon, C.-H., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.2.1507 · Cited by 100
“Experiments with RANKL / mice showed that they do not develop lymph node organogenesis (3) and have abnormal immunological reactions (23).”
BackgroundMolecular and cellular mediators of interleukin-1-dependent acute inflammatory arthritis
Lawlor, K. E., Campbell, I. K., O’Donnell, K., Wu, L., & Wicks, I. P. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200102)44:2<266::aid-anr43>3.0.co;2-g · Cited by 53
DJ-1 controls bone homeostasis through the regulation of osteoclast differentiation
Kim, H. S., Nam, S. T., Mun, S. H., Lee, S., Kim, H., Park, Y. H., Kim, B., Won, K., Kim, H., Park, Y., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01527-y · Cited by 104
RANKL-independent modulation of osteoclastogenesis
Feng, W., Guo, J., & Li, M. (2019) · Journal of Oral Biosciences · doi:10.1016/j.job.2019.01.001 · Cited by 103
Takami, M., Mochizuki, A., Yamada, A., Tachi, K., Zhao, B., Miyamoto, Y., Anada, T., Honda, Y., Inoue, T., Nakamura, M., et al. (2009) · Tissue Engineering Part A · doi:10.1089/ten.tea.2009.0065 · Cited by 99
“OPGL=RANKL-deficient mice develop osteopetrosis due to a defect of osteoclast differentiation, which shows that RANKL is an essential factor for osteoclast differentiation in vivo.(41) We speculated that osteoclast differentiation induced through stimulation by the intrinsic chemical nature of OCP may depend on upregu…”
MCP-1 expressed by osteoclasts stimulates osteoclastogenesis in an autocrine/paracrine manner
Miyamoto, K., Ninomiya, K., Sonoda, K., Miyauchi, Y., Hoshi, H., Iwasaki, R., Miyamoto, H., Yoshida, S., Sato, Y., Morioka, H., et al. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.04.020 · Cited by 107
Interleukin-33 stimulates formation of functional osteoclasts from human CD14+ monocytes
Mun, S. H., Ko, N. Y., Kim, H. S., Kim, J. W., Kim, D. K., Kim, A., Lee, S. H., Kim, Y., Lee, C. K., Lee, S. H., et al. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0410-y · Cited by 105
“Osteoclastogenesis is classically regulated by macrophage colony-stimulating factor (M-CSF) [6] and the receptor activator of NF-jB ligand (RANKL) [7].”
BackgroundChagraoui, H., Tulliez, M., Smayra, T., Komura, E., Giraudier, S., Yun, T. J., Lassau, N., Vainchenker, W., & Wendling, F. (2003) · Blood · doi:10.1182/blood-2002-09-2839 · Cited by 107
Grčević, D., Lee, S.-K., Marušić, A., & Lorenzo, J. A. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.8.4231 · Cited by 99
“Receptor activator of NFkB ligand (RANK-L)(3) is a key regulator of osteoclastogenesis (14), which can both activate mature osteoclasts and mediate osteoclastogenesis in the presence of M-CSF (15).”
BackgroundThe role of osteoprotegerin in cardiovascular disease
Montagnana, M., Lippi, G., Danese, E., & Guidi, G. C. (2012) · Annals of Medicine · doi:10.3109/07853890.2012.727019 · Cited by 104
RANK, RANKL and osteoprotegerin in arthritic bone loss
Bezerra, M. C., de Carvalho, J. F., Prokopowitsch, A. S., & Pereira, R. M. R. (2005) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2005000200004 · Cited by 115
“Consequently, OPG is an effective inhibitor of osteoclast maturation and osteoclast activation in vitro and in vivo (8,13).”
BackgroundRANKL subcellular trafficking and regulatory mechanisms in osteocytes
Honma, M., Ikebuchi, Y., Kariya, Y., Hayashi, M., Hayashi, N., Aoki, S., & Suzuki, H. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1941 · Cited by 98
“S1D, RANK beads added to osteoblasts from the opposite side of the membrane did not capture RANKL, whereas beads added to osteocytes from the opposite side of the membrane captured RANKL.”
BackgroundInfluentialRANKL, denosumab, and giant cell tumor of bone
Thomas, D. M. (2012) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328354c129 · Cited by 104
“Amgen, who were heavily involved in the initial discoveries of RANKL biology [85,89,90], developed a fully human monoclonal antibody to RANKL (denosumab).”
BackgroundSo, H., Rho, J., Jeong, D., Park, R., Fisher, D. E., Ostrowski, M. C., Choi, Y., & Kim, N. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m302940200 · Cited by 97
Development of Proteoglycan-Induced Arthritis Is Independent of IL-17
Doodes, P. D., Cao, Y., Hamel, K. M., Wang, Y., Farkas, B., Iwakura, Y., & Finnegan, A. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.1.329 · Cited by 98
“IL-17 induces the expression of RANKL in osteoblasts and RANKL is an important regulator of osteoclastogenesis (37, 48).”
BackgroundMorony, S., Warmington, K., Adamu, S., Asuncion, F., Geng, Z., Grisanti, M., Tan, H. L., Capparelli, C., Starnes, C., Weimann, B., et al. (2005) · Endocrinology · doi:10.1210/en.2004-1583 · Cited by 97
Self-citationExpression and function of TNF-family proteins and receptors in human osteoblasts>
Bu, R., Borysenko, C. W., Li, Y., Cao, L., Sabokbar, A., & Blair, H. C. (2003) · Bone · doi:10.1016/j.bone.2003.07.006 · Cited by 106
“The discovery that TNF-family cytokines are critically important in normal bone turnover, RANKL in particular [4–6,8], and in the development of rheumatoid arthritis, TNF in particular [11,12], made occurrence and function of TNF-family proteins and receptors in bone an important issue.”
Background
Metadata
- Authors
- Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., Khoo, W., Wakeham, A., Dunstan, C. R., Lacey, D. L., Mak, T. W., Boyle, W. J., & Penninger, J. M.
- Affiliations
- University of Toronto (CA)
- Amgen (United States) (US)
- Corresponding author
- Penninger, Josef M.
- Venue
- Nature
- Published
- 1999-01
- Volume
- 397
- Issue
- 6717
- Pages
- 315-323
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1534645474
- Cited by
- 3,351
- References
- 52
- Citations by year
- 2026: 27 · 2025: 47 · 2024: 58 · 2023: 71 · 2022: 88 · 2021: 114 · 2020: 121 · 2019: 102 · 2018: 95 · 2017: 115 · 2016: 107 · 2015: 125 · 2014: 119 · 2013: 138 · 2012: 162
- FWCI
- 49.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
- Keywords
- osteoprotegerin ligand, RANKL, osteoclastogenesis, osteopetrosis, tooth eruption, lymphocyte development, dendritic cells, T cell development, B cell development, osteoblasts
- MeSH terms
- Animals, B-Lymphocytes, Carrier Proteins, Cell Differentiation, Cells, Cultured, Dendritic Cells, Female, Embryonic and Fetal Development, Growth Substances, Hematopoiesis, Extramedullary, Hematopoietic Stem Cells, Lymph Nodes, Lymphocyte Activation, Lymphocytes, Male, Membrane Glycoproteins, Mice, Inbred BALB C, Mice, Inbred C57BL, Molecular Sequence Data, Osteoclasts, Osteogenesis, Osteopetrosis, T-Lymphocytes, Thymus Gland, Cytokines, Mutagenesis, Bone Remodeling, Gene Targeting, Leukopoiesis, Mice, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.